Ann: Half Yearly Report and Accounts, page-9

It is all about MC and EV. NYR now trading at above $20m, EV $ 15m for just 1 pre-clinical asset. If that 15m is fairly valued then CHM's current EV of just $6m should be several hundreds of millions considering the stage of development of CHM's assets and world's best clinical data. Treating both, brain injuries and brain cancer, is important but I don't think that GBM is worth nothing to what NYR got.

But NYR shows when the board let's the market have its say and let it run before a CR then a premium will be achieved. That is what makes the difference between Discount-Hopper and NYR decision makers. There is plenty of money out there, Hopper either insanely refused to take it or deliberately sank the 3 comps to provide a very low entry for his mates. Both would be legal but highly unethical.

GLTA